{"id":"W4387451565","doi":"10.1038/s41591-023-02598-9","title":"ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results","year":2023,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":150,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen's University; Kingston Health Sciences Centre; University Health Network; Hamilton Health Sciences; Juravinski Cancer Centre; Princess Margaret Cancer Centre; Ottawa Hospital; BC Cancer Agency","funders":"National Cancer Institute; Novartis Pharmaceuticals Canada; EMD Serono; Genentech; National Institutes of Health; Jazz Pharmaceuticals; Regeneron Pharmaceuticals; GlaxoSmithKline; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; Johns Hopkins University; Amgen; Pfizer; Daiichi Sankyo Europe; Sanofi; Cancer Research Institute","keywords":"Medicine; Internal medicine; Response Evaluation Criteria in Solid Tumors; Clinical endpoint; Pembrolizumab; Oncology; Lung cancer; Confidence interval; Progression-free survival; Randomized controlled trial; Immunotherapy; Phases of clinical research; Cancer; Chemotherapy","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005993842,0.0002098367,0.0002699875,0.0001785284,0.00003775541,0.000008843577,0.0001965827,0.0004299512,0.00002893727],"category_scores_gemma":[0.0006562411,0.0001798016,0.00007101292,0.0003643243,0.00007636863,0.000002207337,0.0001080555,0.0004341127,0.000007910611],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007942478,"about_ca_system_score_gemma":0.0002823858,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001729651,"about_ca_topic_score_gemma":0.000574639,"domain_scores_codex":[0.9985511,0.00008329432,0.0003388892,0.0004846182,0.0001910733,0.0003510174],"domain_scores_gemma":[0.9991229,0.0001542433,0.0001031064,0.0003936646,0.00009645468,0.0001295902],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6845552,0.0002395552,0.0004221501,0.00006051238,0.00006448472,0.0004212472,0.000884948,0.0002046887,0.182401,0.00001364142,0.1273909,0.003341569],"study_design_scores_gemma":[0.510803,0.01265279,0.01761577,0.0005669951,0.0002598548,0.00001846216,0.0006177302,0.002555763,0.1211617,0.00009997592,0.3324997,0.001148246],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9871725,0.007533611,0.00003931495,0.002053095,0.001303343,0.0006165459,0.0002836651,0.00001699636,0.0009808688],"genre_scores_gemma":[0.99275,0.002069624,0.00005419387,0.00111412,0.001947671,0.000172659,0.0002806115,0.00003378947,0.001577258],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2051088,"threshold_uncertainty_score":0.7332096,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.00815115059855832,"score_gpt":0.3022338058159968,"score_spread":0.2940826552174385,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}